{"organizations": [], "uuid": "41a7c4ac944a3285402b6dc24fb0bb0636f78e13", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/buzz-axovant-sciences-slumps-as-key-drug/buzz-axovant-sciences-slumps-as-key-drug-program-scrapped-idUSL4N1P33M1", "country": "US", "domain_rank": 408, "title": "BUZZ-Axovant Sciences: Slumps as key drug program scrapped", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.108, "site_type": "news", "published": "2018-01-08T20:55:00.000+02:00", "replies_count": 0, "uuid": "41a7c4ac944a3285402b6dc24fb0bb0636f78e13"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/buzz-axovant-sciences-slumps-as-key-drug/buzz-axovant-sciences-slumps-as-key-drug-program-scrapped-idUSL4N1P33M1", "ord_in_thread": 0, "title": "BUZZ-Axovant Sciences: Slumps as key drug program scrapped", "locations": [], "entities": {"persons": [{"name": "axovant", "sentiment": "none"}, {"name": "akankshita mukhopadhyay", "sentiment": "none"}, {"name": "lewy", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "pfizer", "sentiment": "none"}, {"name": "axon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "** Drug developer’s shares plunge 47.1 pct to $2.84 premarket - stock set to open at record low\n** Biggest pct loser among all U.S.-listed stocks premarket\n** Says to discontinue its intepirdine program after the lead experimental treatment failed in a mid-stage study on patients suffering from a type of dementia\n** Neither of the two doses of intepirdine given to patients with dementia with Lewy bodies resulted in improving their motor function, compared with patients given a placebo, Axovant said\n** In Sept, company said it would stop testing its lead drug in Alzheimer’s after it failed to meet the main goals of a late-stage trial\n** Pfizer is abandoning research to find new drugs aimed at treating Alzheimer’s and Parkinson’s disease, the U.S. pharmaceutical company announced on Saturday\n** Up to Friday’s close, AXON stock had fallen 77.9 percent since it announced the failed trial in Sept (Reporting by Akankshita Mukhopadhyay in Bengaluru)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T20:55:00.000+02:00", "crawled": "2018-01-09T17:01:27.000+02:00", "highlightTitle": ""}